Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
GRI Bio, Inc. (GRI)
USD1.62
+0.05 (+3.18%)
US NASDAQ Healthcare Biotechnology
Address
2223 Avenida de la Playa 92037
La Jolla, CA, US
La Jolla, CA, US
CEO
W. Marc Hertz
Website
gribio.com
IPO
2021-02-10
ISIN US3622AW5029
Description
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.62
+0.05 (+3.18%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
108.5K
Beta
-0.66
Float Shares
89.8K
Free Float %
100.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.35% | +2.80% | -12.35% | -11.65% | -96.15% | -68.16% | -94.58% | -100.00% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
1.62
DCF (Unlevered)
65.29
+3,930.3%
DCF (Levered)
83.11
+5,030.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-8.55
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%+92.1% ★ Q1'26: +99.0% (vs Q2'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +1,800.4% (vs Q2'25)
-
Share dilution Biotechnology: -3.4%+1,399.6% Q1'26: +6,513.0% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: -0.01× (vs Q2'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
Dec 2027 1 EPS Ana. |
Dec 2028 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
est: 11.20M (-100.0%)
|
22.54M
est: 22.54M (+0.0%)
|
—
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBITDA |
-10.90M
|
-8.20M
est: 7.37M (-211.2%)
|
-11.97M
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-10.96M
|
-8.21M
est: 7.37M (-211.3%)
|
-11.98M
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-13.04M
est: 1.45B (-100.9%)
|
-8.21M
est: -8.82M (+6.9%)
|
-11.96M
est: -16.17M (+26.1%)
|
-515.8K
-901.6K – -130.1K
+96.8% YoY
|
-277.8K
-519.2K – -36.5K
+46.1% YoY
|
-19.6K
-19.6K – -19.6K
+92.9% YoY
|
| SGA |
8.10M
|
4.46M
est: 68.28M (-93.5%)
|
5.16M
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-140,450.24
est: 7,889.70 (-1,880.2%)
|
-1,545.88
est: -1,347.08 (-14.8%)
|
-121.80
est: -164.78 (+26.1%)
|
-5.26
-9.18 – -1.33
+96.8% YoY
|
-2.84
-5.29 – -0.37
+46.1% YoY
|
-0.20
-0.20 – -0.20
+92.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-19 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-18 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-15 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-14 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-13 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-12 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-11 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-28 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-27 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-12.13M
OE per share TTM
-73.84
Owner's Yield
-444.47%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
4.6%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
6
Total invested
64.7K
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
6
+5 vs prev Q
New positions
5
Closed positions
0
Increased
5
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 18.4K +18.4K (+100.0%) | 42.2K +42.2K (+100.0%) | 1.49% +1.486 pp | 0.00% +0.000 pp | USD2.29 +0.0% | 1 qtrs NEW |
| 2 | UBS GROUP AG | 8.7K +8.7K (+100.0%) | 20.0K +20.0K (+100.0%) | 0.70% +0.703 pp | 0.00% +0.000 pp | USD2.29 +0.0% | 1 qtrs NEW |
| 3 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.1K +1.1K (+100.0%) | 2.4K +2.4K (+100.0%) | 0.09% +0.085 pp | 0.00% +0.000 pp | USD2.29 +0.0% | 1 qtrs NEW |
| 4 | BLACKROCK, INC. | 7.00 +7.0 (+100.0%) | 16.00 +16.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD2.29 +0.0% | 1 qtrs NEW |
| 5 | SBI SECURITIES CO., LTD. | 4.00 -113.0 (-96.6%) | 9.00 -20.0 (-69.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD6.50 -64.8% | 2 qtrs — |
| 6 | DANSKE BANK A/S | 2.00 +2.0 (+100.0%) | 5.00 +5.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.00 +14.5% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 4 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR Dow Jones International Real Estate ETF RWX | 0.38% | 1.04M | 0.59% |
| 2 | State Street SPDR Dow Jones Global Real Estate ETF RWO | 0.10% | 1.27M | 0.50% |
| 3 | State Street SPDR Portfolio Europe ETF SPEU | 0.01% | 65.5K | 0.07% |
| 4 | Vanguard Extended Market ETF VXF | 0.00% | 44.1K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
11
Sells
0
Shares acquired
99.8K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+99,780
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-18 | Szekeres David Leslie | Director | A-Award | A | Stock Option (Right to Buy) | 39,897 | 1.93 | 77.0K | 39,897 | D | ↗ |
| 2025-09-18 | SIMPSON CAMILLA V | Director | A-Award | A | Stock Option (Right to Buy) | 23,605 | 1.93 | 45.6K | 23,605 | D | ↗ |
| 2025-09-18 | Rongen Roelof | Director | A-Award | A | Stock Option (Right to Buy) | 23,605 | 1.93 | 45.6K | 23,605 | D | ↗ |
| 2025-09-18 | Kelly Leanne | Officer | A-Award | A | Stock Option (Right to Buy) | 43,222 | 1.93 | 83.4K | 43,222 | D | ↗ |
| 2025-09-18 | Hertz Walter Marc | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 103,067 | 1.93 | 198.9K | 103,067 | D | ↗ |
| 2025-09-18 | Chaturvedi Vipin | Officer | A-Award | A | Stock Option (Right to Buy) | 43,222 | 1.93 | 83.4K | 43,222 | D | ↗ |
| 2025-09-18 | Baker David Charles | Director | A-Award | A | Stock Option (Right to Buy) | 23,605 | 1.93 | 45.6K | 23,605 | D | ↗ |
| 2025-08-26 | Szekeres David Leslie | Director | A-Award | A | Stock Option (Right to Buy) | 10,276 | 1.41 | 14.5K | 10,276 | D | ↗ |
| 2025-08-26 | SIMPSON CAMILLA V | Director | A-Award | A | Stock Option (Right to Buy) | 5,994 | 1.41 | 8.5K | 5,994 | D | ↗ |
| 2025-08-26 | Rongen Roelof | Director | A-Award | A | Stock Option (Right to Buy) | 5,994 | 1.41 | 8.5K | 5,994 | D | ↗ |
| 2025-08-26 | Kelly Leanne | Officer | A-Award | A | Stock Option (Right to Buy) | 11,854 | 1.41 | 16.7K | 11,854 | D | ↗ |
| 2025-08-26 | Hertz Walter Marc | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 26,688 | 1.41 | 37.6K | 26,688 | D | ↗ |
| 2025-08-26 | Chaturvedi Vipin | Officer | A-Award | A | Stock Option (Right to Buy) | 11,854 | 1.41 | 16.7K | 11,854 | D | ↗ |
| 2025-08-26 | Baker David Charles | Director | A-Award | A | Stock Option (Right to Buy) | 5,994 | 1.41 | 8.5K | 5,994 | D | ↗ |
| 2025-08-13 | Szekeres David Leslie | Director | A-Award | A | Stock Option (Right to Buy) | 7,545 | 1.30 | 9.8K | 7,545 | D | ↗ |
| 2025-08-13 | SIMPSON CAMILLA V | Director | A-Award | A | Stock Option (Right to Buy) | 4,527 | 1.30 | 5.9K | 4,527 | D | ↗ |
| 2025-08-13 | Rongen Roelof | Director | A-Award | A | Stock Option (Right to Buy) | 4,527 | 1.30 | 5.9K | 4,527 | D | ↗ |
| 2025-08-13 | Baker David Charles | Director | A-Award | A | Stock Option (Right to Buy) | 4,527 | 1.30 | 5.9K | 4,527 | D | ↗ |
| 2025-01-23 | Szekeres David Leslie | Director | A-Award | A | Stock Option (Right to Buy) | 51,937 | 0.69 | 35.6K | 51,937 | D | ↗ |
| 2025-01-23 | SIMPSON CAMILLA V | Director | A-Award | A | Stock Option (Right to Buy) | 30,297 | 0.69 | 20.8K | 30,297 | D | ↗ |
| 2025-01-23 | Rongen Roelof | Director | A-Award | A | Stock Option (Right to Buy) | 30,297 | 0.69 | 20.8K | 30,297 | D | ↗ |
| 2025-01-23 | Kelly Leanne | Officer | A-Award | A | Stock Option (Right to Buy) | 43,319 | 0.69 | 29.7K | 43,319 | D | ↗ |
| 2025-01-23 | Hertz Walter Marc | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 129,730 | 0.69 | 89.0K | 129,730 | D | ↗ |
| 2025-01-23 | Chaturvedi Vipin | Officer | A-Award | A | Stock Option (Right to Buy) | 43,319 | 0.69 | 29.7K | 43,319 | D | ↗ |
| 2025-01-23 | Baker David Charles | Director | A-Award | A | Stock Option (Right to Buy) | 30,297 | 0.69 | 20.8K | 30,297 | D | ↗ |
Executive team
Top executives
Shares Outstanding
89.8K
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| W. Marc Hertz | Co-Founder, Chief Executive Officer, President & Director | 752.5K | — |
| Leanne Kelly | Chief Financial Officer & Corporate Secretary | 474.7K | female |
| Vipin Kumar | Co-Founder & Chief Scientific Officer | 469.1K | — |
| Albert Agro | Co-Founder & Chief Medical Officer | 461.1K | — |
ESG Rating
ESG Score History
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GRI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
